Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma

Critical Care

Volumn 9, Issue SUPPL. 5, 2005, Pages

  Pusateri, Anthony E ^a   Park, Myung S ^a  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; BLOOD DERIVATIVE; FIBRINOGEN; HEMOSTATIC AGENT; PHOSPHOLIPID DERIVATIVE; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOCYTE CONCENTRATE; THROMBOPLASTIN;

ACIDOSIS; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD PH; CLINICAL STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG MONITORING; HEMODILUTION; HEMOSTASIS; HUMAN; HYPOTHERMIA; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; TEMPERATURE; THROMBOCYTE ACTIVATION; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; CLINICAL LABORATORY TECHNIQUES; FACTOR VII; HOMEOSTASIS; HUMANS; PROTHROMBIN TIME; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; WOUNDS AND INJURIES;

EID: 31744432115     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc3781     Document Type: Review

References (96)

1. Hedner U, Kisiel W: Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983, 71:1836-1841.
2. Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L: Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989, 19:335-343.
3. Jurlander B, Thim L, Klausen NK, Persson E, Kjalke M, Rexen P, Jorgensen TB, Ostergaard PB, Erhardtsen E, Bjorn SE: Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001, 27:373-384.
4. Abshire T, Kenet G: Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004, 2: 899-909.
5. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y, for the NovoSeven Trauma Study Group: Recombinant Factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients. J Trauma 2005, 59: 8-18.
6. Davie EW, Ratnoff OD: Waterfall sequence for intrinsic blood clotting. Science 1964, 145:1310-1312.
7. Gailani D, Broze GJ Jr: Factor XI activation in a revised model of blood coagulation. Science 991, 253:909-912.
8. Osterud B, Rapaport SI: Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sd USA 1977, 74: 5260-5264.
9. Rapaport SI, Rao LV: The tissue factor pathway: how it has become a 'prima ballerina'. Thromb Haemost 1995, 74:7-17.
10. Lawson JH, Kalafatis M, Stram S, Mann KG: A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994, 269:23357-23366.
11. Hoffman M, Monroe DM III: A cell-based model of hemostasis. Thromb Haemost 2001, 85:958-965.
12. Drake TA, Morrissey JH, Edgington TS: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989, 134:1087-1097.
13. Wilcox JN, Smith KM, Schwartz SM, Gordon D: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989, 86:2839-2843.
14. Utter GH, Owings JT, Jacoby RC, Gosselin RC, Paglieroni TG: Injury induces increased monocyte expression of tissue factor: factors associated with head injury attenuate the injury-related monocyte expression of tissue factor. J Trauma 2002, 52:1071-1077.
15. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986, 163:740-745.
16. Gando S: Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost 2001, 27:585-592.
17. Furie B, Furie BC: Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004, 10:171-178.
18. Monkovic DD, Tracy PB: Activation of human factor V by factor Xa and thrombin. Biochemistry 1990, 29:1118-1128.
19. Hoffman M, Monroe DM, III: The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001, 38:6-9.
20. Monroe DM, Hoffman M, Roberts HR: Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis 1996, 7:459-464.
21. Diaz-Ricart M, Estebanell E, Lozano M, Aznar-Salatti J, White JG, Ordinas A, Escolar G: Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions. Haematologica 2000, 85:280-288.
22. Mann KG: Biochemistry and physiology of blood coagulation. Thromb Haemost 1999, 82:165-174.
23. Esmon CT: Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001, 29:S48-S51.
24. Broze GJ, Jr.: Tissue factor pathway inhibitor. Thromb Haemost 1995, 74:90-93.
25. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, et al.: The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997, 99:1351-1360.
26. Lisman T, De Groot PG: Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003, 1:1138-1139.
27. Monroe DM, Hoffman M, Oliver JA, Roberts HR: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997, 99:542-547.
28. van't Veer C, Mann KG: The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. Semin Thromb Hemost 2000, 26:367-372.
29. Butenas S, Brummel KE, Bouchard BA, Mann KG: How factor VIIa works in hemophilia. J Thromb Haemost 2003, 1:1158-1160.
30. Butenas S, Brummel KE, Paradis SG, Mann KG: Influence of factor VIIa and phospholipids on coagulation in 'acquired' hemophilia. Arterioscler Thromb Vasc Biol 2003, 23:123-129.
31. Hoffman M, Monroe DM III, Roberts HR: Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998, 9(Suppl 1):S61-S65.
32. Lisman T, Adelmeijer J, Cauwenberghs S, Van Pampus EC, Heemskerk JW, De Groot PG: Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005, 3:742-751.
33. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers IC, Nieuwenhuis HK, de Groot PG: Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002, 99:175-179.
34. He S, Blomback M, Jacobsson EG, Hedner U: The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVII/FIX. J Thromb Haemost 2003, 1:1215-1219.
35. Levi M: Recombinant factor VIIa: a general hemostatic agent? Not yet. J Thromb Haemost 2004, 2:1695-1697.
36. Roberts HR: Recombinant factor VIIa: a general hemostatic agent? Yes. J Thromb Haemost 2004, 2:1691-1694.
37. Armand R, Hess JR: Treating coagulopathy in trauma patients. Transfus Med Rev 2003, 17:223-231.
38. Meng ZH, Wolberg AS, Monroe DM, III, Hoffman M: The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003, 55:886-891.
39. Gende OA: Capacitative calcium influx and intracellular pH cross-talk in human platelets. Platelets 2003, 14:9-14.
40. 2+ entry. Thromb Res 2001, 104:353-360.
41. Martinowitz U, Michaelson M: Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005, 3:640-648.
42. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, Scalea TM: Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004, 57:709-718.
43. O'Neill PA, Bluth M, Gloster ES, Wali D, Priovolos S, DiMaio TM, Essex DW, Catanese CA, Strauss RA: Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002, 52:400-405.
44. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M: Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001, 51:431-438.
45. Kermode JC, Zheng Q, Milner EP: Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999, 94:199-207.
46. Arnal D, Pineiro P, Garutti I, Olmedilla L, Sanz J, Lajara A: Recombinant activated factor VII used in a man with refractory bleeding from a stab wound injuring the liver and kidney (in Spanish]. Rev Esp Anestesiol Reanim 2004, 51:284-288.
47. Martinowitz U, Zaarur M, Yaron BL, Blumenfeld A, Martonovits G: Treating traumatic bleeding in a combat setting: possible role of recombinant activated factor VII. Mil Med 2004, 169:16-8, 4.
48. Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM, Hoots K: The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma 2002, 53:252-257.
49. Martinowitz U, Holcomb JB, Pusateri AE, Stein M, Onaca N, Freidman M, Macaitis JM, Castel D, Hedner U, Hess JR: Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001, 50:721-729.
50. Klemcke HG, Delgado A, Holcomb JB, Ryan KL, Burke A, Deguzman R, Scherer M, Cortez D, Uscilowicz J, Macaitis JM, et al.: Effect of recombinant FVIIa in hypothermic, coagulopathic pigs with liver injuries. J Trauma 2005, 59:155-161.
51. Jones KC, Mann KG: A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994, 269:23367-23373.
52. Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR: Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989, 66:603-609.
53. Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O: Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang 2004, 87:34-40.
54. Chuansumrit A, Nuntnarumit P, Okascharoen C, Teeraratkul S, Suwansingh S, Supapannachart S: The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics 2002, 110:169-171.
55. Hoffman R, Mahajana A, Agmon P, Baruch Y, Brenner B: Successful use of recombinant activated factor VII (Novoseven) in controlling severe intra-abdominal bleeding after liver needle biopsy. Thromb Haemost 2002, 87:346-347.
56. Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999, 354: 1879.
57. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E: Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002, 49:S15-S20.
58. Moscardo F, Perez F, de la Rubia J, Balerdi B, Lorenzo JI, Senent ML, Aznar I, Carceller S, Sanz MA: Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001, 114:174-176.
59. Segal S, Shemesh IY, Blumental R, Yoffe B, Laufer N, Mankuta D, Mazonr M, Zohar S, Schiff E, Martinovitz U: The use of recombinant factor VIIa in severe postpartum hemorrhage. Acta Obstet Gynecol Scand 2004, 83:771-772.
60. Tobias JD, Groeper K, Berkenbosch JW: Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J 2003, 96:12-16.
61. Tobias JD: Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children. Anesthesiology 2002, 96:1522-1525.
62. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT: Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003, 53:34-38.
63. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C: Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004, 44:1325-1331.
64. Carr ME, Jr., Martin EJ: Recombinant factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential. Exp Rev Cardiovasc Ther 2004, 2:661-674.
65. Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004, 104:3858-3864.
66. Key NS, Nelsestuen GL: Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Semin Hematol 2004, 41:51-54.
67. Eikelboom JW, Bird R, Blythe D, Coyle L, Gan E, Harvey M, Isbister J, Leahy M, McIlroy D, Rahimpanah F, et al.: Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003, 14:713-717.
68. Moisescu E, Ardelean L, Simion I, Muresan A, Ciupan R: Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagul Fibrinolysis 2000, 11:575-577.
69. Bernstein DE, Jeffers L, Erhardltsen E, Reddy KR, Glazer S, Squiban P, Bech R, Hedner U, Schiff ER: Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997, 113:1930-1937.
70. Chuansumrit A, Treepongkaruna S, Phuapradit P: Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 2001, 85:748-749.
71. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U: The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998, 9:741-748.
72. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003, 361:201-205.
73. Girard P, Nony P, Erhardtsen E, Delair S, Ffrench P, Dechavanne M, Boissel JP: Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Haemost 1998, 80:109-113.
74. Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E: Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002, 123:118-126.
75. Jeroukhimov I, Jewelewicz D, Zaias J, Hensley G, MacLeod J, Cohn SM, Rashid Q, Pernas F, Ledford MR, Gomez-Fein E, et al.: Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma 2002, 53:1053-1057.
76. Lodge JP, Jonas S, Oussoultzoglou E, Malago M, Jayr C, Cherqui D, Anthuber M, Mirza DF, Kuhlman L, Bechstein WO, et al.: Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005, 102:269-275.
77. Pusateri AE, Ryan KL, Delgado AV, Martinez RS, Uscilowicz JM, Cortez DS, Martinowitz U: Effects of increasing doses of activated recombinant factor VII on haemostatic parameters in swine. Thromb Haemost 2005, 93:275-283.
78. Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM, Aoki N, Meng ZH, Tweardy DJ, Hoots K: The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries. J Am Coll Surg 2003, 196:691-697.
79. Sondeen JL, Pusateri AE, Hedner U, Yantis LD, Holcomb JB: Recombinant factor VIIa increases the pressure at which rebleeding occurs in porcine uncontrolled aortic hemorrhage model. Shock 2004, 22:163-168.
80. Rao LV, Rapaport SI: Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990, 75:1069-1073.
81. Shima M: Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Semin Hematol 2004, 41:125-131.
82. Meijer K, Hendriks HG, de Wolf JT, Klompmaker IJ, Lisman T, Hagenaars AA, Sloof MJ, Porte RJ, van der Meer J: Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 2003, 14:169-174.
83. Cid AR, Lorenzo JI, Haya S, Montoro JM, Casana P, Aznar JA: A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia 2001, 7:39-41.
84. Chuansumrit A, Suwannuraks M, Sri-Udomporn N, Pongtanakul B, Worapongpaiboon S: Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003, 14:187-190.
85. Potapov EV, Pasic M, Bauer M, Hetzer R: Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device. Ann Thorac Surg 2002, 74:2182-2183.
86. Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thomsen HF, Erhardtsen E, Giangrande PL: Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004, 10:352-359.
87. Hemker HC, Giesen, P, AlDieri R, Regnault V, deSmed E, Wagenvoord R, Lecompte T, Beguin S: The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002, 32: 249-253.
88. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J: Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003, 1:551-558.
89. Sorensen B, Ingerslev J: Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol 2004, 41:140-144.
90. Sorensen B, Ingerslev J: Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004, 2:102-110.
91. Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der MJ: An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001, 93:287-289.
92. Hendriks HG, Meijer K, de Wolf JT, Porte RJ, Klompmaker IJ, Lip H, Sloof MJ, van der Meer J: Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002, 13: 309-313.
93. Tanaka KA, Waly AA, Cooper WA, Levy JH: Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003, 98:1513-1515.
94. Cariappa R, Wilhite TR, Parvin CA, Luchtman-Jones L: Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003, 25:474-479.
95. Almeida AM, Khair K, Hann I, Liesner R: The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003, 121:477-481.
96. Gabriel DA, Carr M, Roberts HR: Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol 2004, 41:20-24.